Travere Therapeutics (TVTX) EBIAT (2016 - 2025)
Historic EBIAT for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $25.7 million.
- Travere Therapeutics' EBIAT rose 14689.93% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.5 million, marking a year-over-year increase of 7480.78%. This contributed to the annual value of -$321.5 million for FY2024, which is 1455.84% up from last year.
- Travere Therapeutics' EBIAT amounted to $25.7 million in Q3 2025, which was up 14689.93% from -$12.8 million recorded in Q2 2025.
- In the past 5 years, Travere Therapeutics' EBIAT ranged from a high of $150.7 million in Q3 2023 and a low of -$136.1 million during Q1 2024
- For the 5-year period, Travere Therapeutics' EBIAT averaged around -$54.6 million, with its median value being -$70.4 million (2024).
- Its EBIAT has fluctuated over the past 5 years, first crashed by 676670.79% in 2021, then surged by 27931.19% in 2023.
- Travere Therapeutics' EBIAT (Quarter) stood at -$88.8 million in 2021, then increased by 3.53% to -$85.6 million in 2022, then decreased by 5.3% to -$90.2 million in 2023, then skyrocketed by 33.17% to -$60.3 million in 2024, then skyrocketed by 142.66% to $25.7 million in 2025.
- Its EBIAT was $25.7 million in Q3 2025, compared to -$12.8 million in Q2 2025 and -$41.2 million in Q1 2025.